Researchers at the University of California, Davis have developed a process of administering inhibitors of Interleukin 10 (IL-10) signaling concomitantly with a vaccine or other immunostimulus, so that responses to vaccination occur in the absence of such signaling.
Many vaccine candidates do not induce sufficiently robust immune responses, or do not induce them quickly enough for protection against the target condition. All vaccines stimulate the immune system, but different kinds of vaccines provoke quantitatively and qualitatively different immune responses. For example, some vaccines provoke robust antibody responses but few T cells, some vaccines provoke responses that persist primarily in the "central memory" T cell compartment as opposed to the "effector memory" compartment, and so on, with each vaccine expected and known to elicit primarily a particular kind of immune response in recipients. Each pathogen or undesirable health condition usually can be prevented or treated by only some of these immune responses, however, other induced immune responses are irrelevant or detrimental to the aim of protecting patients. In some cases immune response problems arise due to functioning of regulatory immunologic mechanisms such as Interleukin 10 (IL-10) production and signaling.
Researchers at the University of California, Davis have developed a process of administering inhibitors of IL-10 signaling concomitantly with a vaccine or other immunostimulus, so that responses to vaccination occur in the absence of such signaling. This technology introduces a way of co-administering an inhibitor or Inhibitors of IL-10 signaling with an available vaccine, thereby changing the character and intensity of the immune response generated. By modifying the generated immune responses, there is potential to generate vaccines with superior protection against the disease target.
IL 10, IL inhibitors, Interleukin 10, immune response, vaccine, immunotherapy, human cytokine synthesis inhibitory factor, CSIF